碳青霉烯类耐药铜绿假单胞菌耐药机制与治疗现状

doi:10.12372/jcp.2023.23e0487

Abstract

Abstract:

Pseudomonas aeruginosa is a common opportunistic pathogen of nosocomial infection, which is widely distributed in the hospital environment and can survive for a long time. Carbapenems antibiotics play an important role in the treatment of serious infections caused by Pseudomonas aeruginosa. However, the outbreak of carbapenems resistant Pseudomonas aeruginosa is particularly prominent in recent years, which has made clinical treatment facing great challenges. This article introduces the main resistance mechanism of Pseudomonas aeruginosa to carbapenems antibiotics and summarizes the application of various clinical treatment schemes, and provides a reference clinical rational use of antibiotics and treatment of carbapenems resistant Pseudomonas aeruginosa infection

Key words: Pseudomonas aeruginosa, carbapenem antibiotics, resistance mechanism, treatment

YU Hui. Resistance mechanism and treatment of carbapenem resistant Pseudomonas aeruginosa[J].Journal of Clinical Pediatrics, 2023, 41(8): 561-565.

References 31

[1]	Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis[J]. Lancet Infect Dis, 2018, 18(3): 318-327. doi: S1473-3099(17)30753-3 pmid: 29276051
[2]	Fu P, Xu H, Jing C, et al. Bacterial epidemiology and antimicrobial resistance profiles in children reported by the ISPED program in China, 2016 to 2020[J]. Microbiol Spectr, 2021, 9(3): e0028321.
[3]	Logan LK, Gandra S, Mandal S, et al. Multidrug- and carbapenem-resistant Pseudomonas aeruginosa in children, United States, 1999-2012[J]. J Pediatr Infect Dis Soc, 2017, 6(4): 352-359.
[4]	Seifert H, von Linstow Ml, Janssen H, et al. Antimicrobial susceptibility among Gram-negative isolates in pediatric patients in Europe from 2013-2018 compared to 2004-2012: results from the ATLAS surveillance study[J]. Int J Antimicrob Agents, 2021, 58(5): 106441. doi: 10.1016/j.ijantimicag.2021.106441
[5]	Blair JM, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance[J]. Nat Rev Microbiol, 2015, 13(1): 42-51. doi: 10.1038/nrmicro3380 pmid: 25435309
[6]	Hancock RE, Brinkman FS. Function of Pseudomonas porins in uptake and efflux[J]. Annu Rev Microbiol, 2002, 56: 17-38. pmid: 12142471
[7]	Feng W, Huang Q, Wang Y, et al. Changes in the resistance and epidemiological characteristics of Pseudomonas aeruginosa during a ten-year period[J]. J Microbiol Immunol Infect, 2021, 54(2): 261-266. doi: 10.1016/j.jmii.2019.08.017
[8]	Daury L, Orange F, Taveau JC, et al. Tripartite assembly of RND multidrug efflux pumps[J]. Nat Commun, 2016, 7: 10731. doi: 10.1038/ncomms10731 pmid: 26867482
[9]	Dreier J, Ruggerone P. Interaction of antibacterial compounds with RND efflux pumps in Pseudomonas aeruginosa[J]. Front Microbiol, 2015, 6: 660. doi: 10.3389/fmicb.2015.00660 pmid: 26217310
[10]	Hassuna NA, Darwish MK, Sayed M, et al. Molecular epidemiology and mechanisms of high-level resistance to meropenem and imipenem in Pseudomonas aeruginosa[J]. Infect Drug Resist, 2020, 13: 285-293. doi: 10.2147/IDR.S233808 pmid: 32099420
[11]	Bonnin RA, Bogaerts P, Girlich D, et al. Molecular characterization of OXA-198 carbapenemase-producing Pseudomonas aeruginosa clinical isolates[J]. Antimicrob Agents Chemother, 2018, 62(6): e02496-17.
[12]	Reyes J, Komarow L, Chen L, et al. Global epidemiology and clinical outcomes of carbapenem-resistant Pseu-domonas aeruginosa and associated carbapenemases (POP): a prospective cohort study[J]. Lancet Microbe, 2023, 4(3): e159-e170.
[13]	Schauer J, Gatermann SG, Hoffmann D, et al. GPC-1, a novel class A carbapenemase detected in a clinical Pseudomonas aeruginosa isolate[J]. J Antimicrob Chemother, 2020, 75(4): 911-916. doi: 10.1093/jac/dkz536
[14]	Yin S, Chen P, You B, et al. Molecular typing and carbapenem resistance mechanisms of Pseudomonas aeruginosa isolated from a Chinese burn center from 2011 to 2016[J]. Front Microbiol, 2018, 9: 1135. doi: 10.3389/fmicb.2018.01135
[15]	Breidenstein EB, de la Fuente- Núñez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance[J]. Trends Microbiol, 2011, 19(8): 419-426. doi: 10.1016/j.tim.2011.04.005 pmid: 21664819
[16]	Botelho J, Grosso F, Peixe L. Antibiotic resistance in Pseudomonas aeruginosa - mechanisms, epidemiology and evolution[J]. Drug Resist Updat, 2019, 44: 100640. doi: 10.1016/j.drup.2019.07.002
[17]	Botelho J, Grosso F, Peixe L. Characterization of the pJB12 plasmid from Pseudomonas aeruginosa reveals Tn 6352, a novel putative transposon associated with mobilization of the bla_VIM-2-harboring In58 integron[J]. Antimicrob Agents Chemother, 2017, 61(5): e02532-16.
[18]	van der Zee A, Kraak WB, Burggraaf A, et al. Spread of carbapenem resistance by transposition and conjugation among Pseudomonas aeruginosa[J]. Front Microbiol, 2018, 9: 2057. doi: 10.3389/fmicb.2018.02057
[19]	Xiong J, Alexander DC, Ma JH, et al. Complete sequence of pOZ176, a 500-kilobase IncP-2 plasmid encoding IMP-9-mediated carbapenem resistance, from outbreak isolate Pseudomonas aeruginosa 96[J]. Antimicrob Agents Chemother, 2013, 57(8): 3775-3782. doi: 10.1128/AAC.00423-13
[20]	López-Causapé C, Cabot G, Del Barrio-Tofiño E, et al. The versatile mutational resistome of Pseudomonas aeruginosa[J]. Front Microbiol, 2018, 9: 685. doi: 10.3389/fmicb.2018.00685 pmid: 29681898
[21]	Stewart PS. Mechanisms of antibiotic resistance in bacterial biofilms[J]. Int J Med Microbiol, 2002, 292(2): 107-113. doi: 10.1078/1438-4221-00196 pmid: 12195733
[22]	Pang Z, Raudonis R, Glick BR, et al. Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies[J]. Biotechnol Adv, 2019, 37(1): 177-192. doi: 10.1016/j.biotechadv.2018.11.013
[23]	Rasamiravaka T, Labtani Q, Duez P, et al. The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms[J]. Biomed Res Int, 2015: 759348.
[24]	Chambonnier G, Roux L, Redelberger D, et al. The hybrid histidine kinase lads forms a multicomponent signal transduction system with the GacS/GacA two-component system in Pseudomonas aeruginosa[J]. PLoS Genet, 2016, 12(5): e1006032.
[25]	Bordi C, Lamy MC, Ventre I, et al. Regulatory RNAs and the HptB/RetS signalling pathways fine-tune Pseudomonas aeruginosa pathogenesis[J]. Mol Microbiol, 2010, 76(6): 1427-1443. doi: 10.1111/j.1365-2958.2010.07146.x
[26]	Valentini M, Filloux A. Biofilms and cyclic di-GMP (c-di-GMP) signaling: lessons from Pseudomonas aeruginosa and other bacteria[J]. J Biol Chem, 2016, 291(24): 12547-12555. doi: 10.1074/jbc.R115.711507 pmid: 27129226
[27]	Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 guidance on the treatment of extended-spectrum beta-lactamase producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa)[J]. Clin Infect Dis, 2022, 75(2): 187-212. doi: 10.1093/cid/ciac268
[28]	中华医学会呼吸病学分会感染学组. 中国铜绿假单胞菌下呼吸道感染诊治专家共识(2022年版)[J]. 中华结核和呼吸杂志, 2022, 45(8): 739-752.
[29]	Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)[J]. Clin Microbiol Infect, 2022, 28(4): 521-547. doi: 10.1016/j.cmi.2021.11.025
[30]	Davido B, Fellous L, Lawrence C, et al. Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome beta-lactam resistance conferred by metallo-beta-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa[J]. Antimicrob Agents Chemother, 2017, 61(9): e01008-17.
[31]	王明贵. 广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制: 中国专家共识[J]. 中国感染与化疗杂志, 2017, 17(1): 82-93.

Resistance mechanism and treatment of carbapenem resistant Pseudomonas aeruginosa

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References 31

Related Articles 15

Metrics

Comments

Recommended 0

[1]	CHENG Yuheng, XU Zizhao, CHEN Ying. Recent advances in the diagnosis and treatment of X-linked hypophosphatemic rickets [J]. Journal of Clinical Pediatrics, 2026, 44(8): 747-754.
[2]	FAN Na, WANG Baoxi, LIN Yan, WANG Chunhui, ZHANG Anding, JIANG Xun. The hazards of functional constipation in children and the progress in its diagnosis and treatment [J]. Journal of Clinical Pediatrics, 2026, 44(4): 355-361.
[3]	. Expert consensus on pre-symptomatic treatment for pediatric spinal muscular atrophy (2025 edition) [J]. Journal of Clinical Pediatrics, 2025, 43(9): 643-651.
[4]	LI Zailing. Clinical characteristics, diagnosis and treatment progress of functional gastrointestinal disorders in infants aged 0-6 months [J]. Journal of Clinical Pediatrics, 2025, 43(8): 563-568.
[5]	LYU Mingjun, LUO Wen, YANG Jinxiang, LIANG Jianying, YAO Zhirong. Progress in pathogenesis and treatment of pediatric generalized pustular psoriasis [J]. Journal of Clinical Pediatrics, 2025, 43(7): 556-562.
[6]	ZHANG Yixin, HONG Siqi. Pharmacologic and upcoming treatment of pediatric narcolepsy [J]. Journal of Clinical Pediatrics, 2025, 43(6): 475-482.
[7]	JIA Shuangzhen, KONG Yan, LIU Qian-chao, ZHU Ailin, WU Jie. Application of precision therapy in pediatric inflammatory bowel disease [J]. Journal of Clinical Pediatrics, 2025, 43(3): 226-232.
[8]	HUANG Liufang, WU Bo, WANG Ying. An analysis of predictive markers for surgical treatment of ulcerative colitis in children [J]. Journal of Clinical Pediatrics, 2025, 43(2): 120-127.
[9]	Birth Defects Prevention and Molecular Genetics Branch of the China Maternal and Child Health Association, Pediatric Genetics Group of the Medical Genetics Physicians Branch of the Chinese Medical Doctor Association, Neurogenetic and Developmental Disorders Section of the China Chapter of the International Neurorestoration Society. Multidisciplinary expert consensus on the prevention, screening, diagnosis, counseling and intervention of neural tube defects [J]. Journal of Clinical Pediatrics, 2025, 43(2): 81-92.
[10]	WANG Shuo, LI Yue, HUANG Lihui. Childhood hearing loss: construction of the screening, diagnosis, and intervention system in China [J]. Journal of Clinical Pediatrics, 2025, 43(12): 883-889.
[11]	CHEN Linrui, QIU Jianhui, ZHANG Qianqian, ZHANG Qin, YAO Yuan, GONG Tianyu, CHEN Jianyong, YANG Jun, JIN Yulian, DUAN Maoli, ZHANG Zhiyuan, ZHANG Qing. Clinical manifestations and diagnostic and therapeutic strategies of single-sided deafness in children [J]. Journal of Clinical Pediatrics, 2025, 43(12): 971-978.
[12]	JIANG Wenxuan, YE Fanghua, XIAO Yixin, YANG Liangchun. Analysis of clinical characteristics and prognostic factors of 45 children with hemophagocytic syndrome [J]. Journal of Clinical Pediatrics, 2025, 43(10): 762-767.
[13]	LUO Zhiqiang, CHEN Li, LU Xinguo, LIAO Jianxiang, LUO Xufeng. The treatment of the first case of presymptomatic spinal muscular atropy in the Chinese Mainland: a case report with 43 months follow-up [J]. Journal of Clinical Pediatrics, 2025, 43(1): 40-44.
[14]	ZHONG Jinhong, WANG Can, CHEN Fang. Progress in the research of infantile fiberoptic bronchoscopy sedation [J]. Journal of Clinical Pediatrics, 2025, 43(1): 50-55.
[15]	HUANG Shiyu, LUO Lijuan, WANG Jing, CHEN Xia, CAO Qing. Early diagnosis, treatment and follow-up of 6 children with autoinflammatory diseases caused by NLRP3 gene variation [J]. Journal of Clinical Pediatrics, 2024, 42(7): 643-647.